Classical Trigeminal Neuralgia and Sodium Channel Mutations

Trigeminal Neuralgia Clinical Trial

Official title:

Classical Trigeminal Neuralgia and Sodium Channel Mutations

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03656497
• Other study ID #: H-15010165
• Status: Completed
• Start date: November 1, 2015
• Est. completion date: August 1, 2018

Study information

• Verified date: August 2018
• Source: Danish Headache Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The most common cause of trigeminal neuralgia is considered to be a neurovascular contact. However, this etiological factor only seem to be present in half of the patient group. Thus the etiology of the other half is unknown.

Gain-of function genetic mutations in voltage gated sodium channels have been hypothesized as playing a role in the etiology of trigeminal neuralgia but it has yet to be confirmed. In recent years gain-of-function mutations have been identified as a causative factor in other pain-diseases presenting with trigeminal neuralgia phenotypic similarities.

Description:

The aim of this study was to indentify VGSC gene mutations, specifically SCN9A, SCN10A and SCN11A genes, in a group of well characterized trigeminal neuralgia patients.

Setting: The study will be conducted at The Danish Headache Center, Rigshospitalet - Glostrup, Denmark (inclusion of patients and written Informed Consent, patient interview, phenotyping/diagnosis, neurological examination, blood sample.

Departments of Neurology and Clinical Genomics of the Maastricht University Medical Center, Maastricht, the Netherlands: Targeted NG Sanger Sequencing

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: August 1, 2018
• Est. primary completion date: August 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

3.1. Inclusion Criteria

Subjects of both sexes with TN must meet the following inclusion criteria to be eligible for participation:

1. Patients must be able to give Signed Informed Consent prior to study entry

2. Patients fulfilling of the ICHD-3 beta diagnostic criteria for classical TN.1

3. Age 18 years or older.

4. Age at debut < 42 years and/or confirmed first-line relative with TN.

5. Respond to sodium channel blockers with a 50% reduction of pain intensity evaluated by both the patient and the examining physician using the visual analog scale (VAS).

3.2. Exclusion Criteria

Subjects will be excluded if one of the following exclusion criteria is met:

1. Psychiatric or mental illness of physical condition that might interfere with the ability of the patients to fill in the Informed Consent and questionnaires.

2. History of herpes zoster in the distribution of the trigeminal nerve ipsilateral to pain, multiple sclerosis or a space-occupying lesion.

3. History indicative of painful posttraumatic trigeminal neuropathy such as previous trauma, surgery or radiation to the trigeminal nerve ipsilateral to pain.

Related Conditions & MeSH terms

• Neuralgia
• Trigeminal Neuralgia

Intervention

Other:
• Observational
No intervention is conducted as the study aim is to explore the link between pheno- and genetype of trigeminal neuralgia

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Danish Headache Center	Maastricht University Medical Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Exploratory study of association between phenotype and genotype of trigeminal neuralgia	To identify genetic mutations, via Sanger Next Generation Sequencing, in either NaV 1.7, NaV1.8 or NaV1.9 encoding genes and link the findings to the phenotype of trigeminal neurlagia patients with a high genetic load.	1 day